A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosed with moderate to severe major depressive disorder

• Willing to use acceptable methods of birth control throughout the study and for 3 months after

• In good general health

Exclusion Criteria:

• No history or current diagnosis of other psychiatric conditions such as bipolar disorder, psychotic disorder, general anxiety disorder, anorexia, obsessive compulsive disorder, post traumatic stress disorder, antisocial personality disorder, mental retardation, pervasive developmental disorder, or cognitive disorder

• No history or presence of drug abuse

• No use of prescription medications or herbal medications other than hormone replacement therapies

• No prior history of heart disease or current significant blood, lung, kidney, liver, heart, breathing, neurologic or thyroid disorders

• No patients who are either pregnant or nursing